Articles On Dimerix (ASX:DXB)

FDA grants conditional approval for commercial brand name QYTOVRA Treatment targets billion-dollar market opportunity in rare FSGS kidney disease Treatment already has orphan drug designation Phase 3 clinical trial is progressing   The US...

Dimerix’s drug granted QYTOVRA as brand name by US FDA Starpharma completes recruitment for VIRALEZE study in UK Invion adds South Korea to list of exclusive territories for Photosoft    FDA says QYTOVRA can be used as DMX-200 brand name...

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Futures have predicted the ASX will open slightly lower today, driven by a mixed afternoon of trading on Wall Street and the underperformance of tech stocks. On home soil, today marks the eagerly awaited High Court decision that will det...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year   Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Peak Asset M...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Dimerix has achieved another key milestone in its ACTION 3 Focal Segmental Glomerulosclerosis (FSGS) trial with the Data  Safety Monitoring Board  (DSMB) safety review giving it the green light to continue as planned. Dimerix (ASX:DXB) has...

Dimerix (ASX:DXB) has announced that the independent Data Safety Monitoring Board has successfully concluded a second review of the ACTION3 phase 3 clinical trial.

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Dimerix (ASX:DXB) has confirmed that the first 72 patients have been randomised in its DMX-200 ACTION3 phase 3 trial in patients with FSGS kidney disease.

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Dimerix has achieved a key milestone in its global Phase 3 Focal Segmental Glomerulosclerosis (FSGS) trial with the last patient of the first 72 patient cohort  now randomised, locking in a March 2024 date for interim outcome results.   Dim...

Futures suggest the ASX will open higher before the release of Australia’s inflation figures and the interest rate decisions from the Federal Reserve and ECB. Meanwhile, the Aussie dollar is down 0.7 per cent to 67.29 US cents. Here...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Peak Asset Management recently held its first Microcaps investor conference, and here’s what the punters and players had to say about it. In mid July, boutique firm Peak Asset Management organised its inaugural microcap investor conference,...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Dimerix (ASX:DXB) has announced that the Paediatric Committee of the European Medicines Agency has accepted its Paediatric Investigation Plan for the development of DMX-200 for focal segmental glomerulosclerosis following the PDCO m...

Peak Asset Management, with the support of Stockhead, is giving you the chance to go 1-on-1 with some of the leading ASX small caps CEOs and property gurus from a range of market sectors in Melbourne, on 13 July, 2023. The hectic landscape...

In a major milestone, Dimerix has received endorsement by the European Medicines Agency (EMA) to include children in Europe in its pivotal ACTION3 trial. Dimerix (ASX:DXB) has announced  that the Paediatric Committee (PDCO) of the EMA has...

Futures suggest the ASX will climb as the new financial year takes off, bolstered by hopes that the RBA will hit pause ahead of its next rates decision tomorrow. Here are some ASX-listed companies with news out today: Larvotto Resourc...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest-performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest-performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

By Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m Chief executive officer: Dr Nina Webster Board: Hugh Alsop (chair), Dr Webster, Dr Sonia Poli, Clinton Snow Financials (March quarter 2023):...

In a tough market environment Dimerix has announced it has raised close to $9 million as it moves to advance its Phase 3 Focal Segmental Glomerulosclerosis (FSGS) clinical trial past first interim data. Clinical stage biopharmaceutical comp...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Stockhead’s In-Case-You-Missed-It highlights some of the strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some of the strongest-performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag...

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms....

Stockhead’s In Case You Missed It highlights some of the strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage...